We are committed to helping people with neurodegenerative disorders through innovative research and development.
Welcome to
Annual General Meeting 2026
BioArctic’s Annual General Meeting will take place on May 28, 2026
May 20, 2026
Interim Report Q1 2026
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s first quarter report for January – March 2026 on Wednesday, May 20, 2026, at 8:00 a.m. CET.
Audiocast with teleconference: at 09:30 CET the same day.
Our Therapeutic Areas of Expertise
We are developing disease modifying treatments against Alzheimer’s disease. Lecanemab is an antibody targeting oligomers and protofibrils, the harmful forms of Aβ.
Due to the wide spread and severity of the disease, combined with a lack of effective pharmaceutical drugs, the need for new and effective treatments is significant.
ALS – Amyotrophic lateral sclerosis
Current treatments include drugs that slow down the disease development or relieve severe symptoms. BioArctic aims for targeting the cause of nerve cell damage.
The blood-brain barrier controls the passage of substances between the bloodstream and the brain. It protects the brain, but can make it difficult to deliver drugs to the brain.
This is BioArctic
BioArctic is a Swedish research oriented biopharma company. Based on our cutting-edge expertise in neurodegenerative disorders, we have built a broad and well-diversified project portfolio with the potential to improve the health of patients. The diversity of projects in various phases of development provides a solid basis for creating value for patients, their families, and society as a whole. This makes us an attractive company to both partners and investors.
Our progress in numbers
-
20
years of world leading research
-
15
research projects
-
5
cooperation principles
Investor contact
